2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3001

Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Abstract Number: 2458

Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Abstract Number: 2169

Targeting ITGAM+ Cells Successfully Treats a Model of Anti-RNP-Associated Pulmonary Hypertension
Abstract Number: 850

Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Abstract Number: 1019

Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056
Abstract Number: 2840

Targeting the RhoA-Rock Pathway to Reverse T Cell Dysfunction in SLE
Abstract Number: 2311

Tele-Rheumatology: Despite Improved Access Could There be a Potential Delay in Care without a Skilled “Presenter”?
Abstract Number: 782

Temporal Artery Microbiome in Giant Cell Arteritis
Abstract Number: 2502

Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
Abstract Number: 2685

Ten-Eleven Translocation 2 Protein Down-Regulates DNA Methylation of Interleukin-17A Promoter and Induces Its Expression in CD4⁺t Cells of Patients with Systemic Lupus Erythematosus
Abstract Number: 308

Tenascin-C, a TLR4 Ligand Levels in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis: Cross-Sectional and Longitudinal Study
Abstract Number: 1045

Tertiary Lymphoid Organ Developmental Program: Diversgent Paradigm of Lymphoid Organogenesis
Abstract Number: 890

Test of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Item Profile in a Large Cohort of Rheumatic Disease Patients
Abstract Number: 3018

Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis
Abstract Number: 859

TGF-β3-Producing CD4⁺CD25^–LAG3⁺ Regulatory T Cells Control B Cell Responses

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].